Combination treatment for hidradenitis suppurativa
Part of Infections, Skin clinical trials.
This study tests a new medicine given by injection (anti-IL-17A/F antibody) combined with a laser treatment (non-ablative dot laser) for people with mild to moderate hidradenitis suppurativa (also called HS). The goal is to see if the combination is safe and works better than current options, and might help reduce pain and flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have mild to moderate hidradenitis suppurativa (Hurley stage I or II).
- You have at least 3 painful lumps or abscesses in at least one area of your body.
- Your disease has not improved with at least 3 months of antibiotic treatment, or you couldn't take antibiotics, or your symptoms came back after stopping them.
- You have not used any biologic medicine (like Humira) or other targeted treatments for HS before.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a 1726-nm laser to reduce inflamed nodules in people with mild to moderate hidradenitis suppurativa (HS). It compares treated and untreated areas to see if the laser helps without affecting the rest of the body.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
This study tests a new treatment that blocks a protein called type 1 interferon, which may reduce inflammation and pain in severe hidradenitis suppurativa. It is for people who have not improved with standard treatments like antibiotics or biologic drugs.
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.